Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces the amount of acid produced in the stomach.
## Primary Indications
* Healing of erosive esophagitis
* Maintenance of healing of erosive esophagitis
* Symptomatic gastroesophageal reflux disease (GERD)
* Dose reduction for patients on long-term dual or triple therapy for *Helicobacter pylori* eradication
## Adult Dosing
* **Erosive Esophagitis (Healing):** 40 mg orally or IV once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. Some patients may be managed on 20 mg orally once daily.
* **Symptomatic GERD:** 40 mg orally once daily for up to 4 weeks. If symptom relief is not achieved, consider further evaluation.
* ***H. pylori* Eradication:** Part of multi-drug regimens. Dosing varies based on the specific regimen and duration, typically involving antibiotics. Common regimens include pantoprazole 40 mg twice daily with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily, or pantoprazole 40 mg twice daily with clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily, for 7-14 days.
## Pediatric Dosing
* **Erosive Esophagitis (Healing):**
* **5 to 11 years:** 20 mg orally once daily for up to 8 weeks.
* **12 to 17 years:** 40 mg orally once daily for up to 8 weeks.
* **Symptomatic GERD:**
* **5 to 17 years:** 20 mg orally once daily for up to 4 weeks.
*Note: IV formulations are not generally recommended for pediatric patients.*
## Dose Adjustments
No dose adjustment is generally required for patients with hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, any other PPI, or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, headache, nausea, abdominal pain, vomiting, flatulence, dizziness.
* **Serious:**
* Bone fracture (hip, wrist, spine) with long-term, high-dose PPI use.
* *Clostridium difficile*-associated diarrhea.
* Hypomagnesemia (can be symptomatic or asymptomatic, may lead to hypocalcemia and hypokalemia).
* Vitamin B12 deficiency.
* Fundic gland polyps.
* Systemic lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Separate administration times by at least 2 hours.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider a temporary discontinuation of pantoprazole if high-dose methotrexate is administered.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel, though clinical significance is debated.
* **Warfarin:** Increased INR and bruising. Monitor INR closely.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, muscle cramps, seizures, arrhythmias).
* Monitor for signs and symptoms of *C. difficile* infection.
* Consider monitoring vitamin B12 levels and magnesium levels in patients on long-term therapy.
* Bone mineral density screening for patients at risk of osteoporosis.
## Clinical Pearls
* Pantoprazole is available in delayed-release oral formulations (tablets, capsules) and as a powder for injection.
* Oral pantoprazole should be taken at least 1 hour before a meal.
* For patients with difficulty swallowing, the delayed-release capsules can be opened and mixed with 2 tablespoons of applesauce or an equivalent food product, then consumed immediately. Do not crush or chew the granules.
* IV administration is typically reserved for situations where oral intake is not possible.
* Long-term use of PPIs is associated with increased risk of fractures, C. difficile infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
***
*Disclaimer: This information is intended for clinical decision support and does not replace independent professional judgment. Always consult the most current prescribing information and relevant clinical guidelines before initiating or modifying therapy.*
